Journal article
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms
J Lindsay, CS Walti, AB Halpern, H Xie, EL Chung, KG Schonhoff, EM Huebner, GS Cheng, LE Kimball, WM Leisenring, M Greenwood, SCA Chen, DCM Kong, MA Slavin, M Boeckh, DN Fredricks, C Liu, SA Pergam, RB Walter, JA Hill
Blood Advances | ELSEVIER | Published : 2023
Abstract
CLAG-M (cladribine, high-dose cytarabine [HiDAC], G-CSF, mitoxantrone)/CLAG are contemporary intensive chemotherapy regimens associated with higher and deeper complete remission rates than 7+3 (cytarabine, anthracycline)/HiDAC, but with greater myelosuppression and potential infection risks. Here, we compared the cumulative incidence (CI) and patterns of invasive fungal disease (IFD) between these regimens by identifying proven/probable and possible cases of IFD following CLAG-M (n=332) and 7+3 (n=115) chemotherapy and subsequent treatment cycles in adults ≥18 years old with newly diagnosed (ND) or relapsed/refractory (R/R) AML or other high-grade myeloid neoplasms between 2006 and 2018. By ..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
& nbsp;J.L. is supported by a Leukaemia Foundation and Haematology Society of Australia and New Zealand New Investigator PhD Scholarship. M.A.S. is supported by National Health and Medical Research Council Centres of Research Excellence and investigator grants (1116876 and 1173791) . This work was supported by a grant from Nohla Therapeutics (now Deverra Therapeutics) .